United States Antimony just saw nearly a quarter of its market value erased in a single session, with the stock closing down about 24% at US$4.97, even though the headline number on the income statement flashed a small profit. The market fixated on the sharp squeeze in gross margin after antimony prices dropped hard, while a US$6.8 million unrealized gain on the Larvotto stake quietly flipped the bottom line into the black.
For investors, this is a sentiment clash: price is reacting to operating pain, while earnings are flattered by the balance sheet.
Like the exposure to antimony through United States Antimony but uneasy about thin margins and one off investment gains doing the heavy lifting on earnings? Consider our list of solid balance sheet and fundamentals stocks (49 results).
Prefer clean charts over another wall of tables and raw figures? Explore United States Antimony’s full visual financial picture, with a focus on its balance sheet strength and capital structure, in our company report for United States Antimony.
Bulls argue United States Antimony is building a secure, scaled domestic antimony platform backed by defense demand and stronger volumes. Q2 does show building blocks. Antimony pounds sold rose 26% and zeolite revenue more than doubled, while first DLA shipments of about 82,000 pounds mark real progress on the government contract. Thompson Falls and Radersburg upgrades moved ahead and inventory rose to US$21.6m to support expected deliveries. Liquidity jumped to about US$105m in cash and marketable securities, which supports the heavy build out narrative. However, the drop in realized antimony pricing to US$13.70 per pound and the 7% gross margin show that higher volumes and new capacity are not yet translating into resilient profitability. The equity gain on Larvotto, not core smelting or mining, is what kept net income positive.
Bears worry that commodity exposure, execution risk and thin margins could cap the upside in United States Antimony even with headline contracts. Q2 supports several of those concerns. Revenue declined 25% year on year despite higher antimony and zeolite volumes, as realized antimony prices fell about 52% and crushed gross margin from 27% to 7%. Operating loss reached roughly US$7.0m and was only masked at the bottom line by a US$6.8m unrealized gain on Larvotto and investment income. Cash outflow from operations and heavy capex underline how dependent the current plan is on fresh capital, highlighted by US$43.4m raised through equity. The stock’s 24% single day drop after earnings and weaker 30 and 90 day returns show the market is treating guidance cuts and margin compression as real risks, not just temporary noise.
Compare whether United States Antimony’s volume gains, DLA contract progress and cash build match what institutional analysts expect from NYSE:UAMY. See the consensus price target analysis for United States Antimony to check if Wall Street is raising or cutting its targets after this 24% post earnings slide.If the sharp margin squeeze and 24% single day drop in United States Antimony have your attention, register for free with Simply Wall St and add the stock to a Watchlist so you can track price against fair value and wait for an entry point that fits your plan. Once you are invested, keep United States Antimony and the rest of your holdings organised in the Portfolio Command Center which focuses your view on key fundamental changes instead of day to day noise. For longer term conviction, tap into the Community to see how other investors are thinking about contracts, margins and balance sheet strength. By surfacing potential catalysts and risks early, Simply Wall St helps you act with confidence and stay ahead of the market.
Markets move fast and the best breakout stories often fly under the radar for now. Spot fresh momentum and avoid getting caught chasing late moves. Get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com